Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent - Test2 - elhamkhani - TriplyDB

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

http://www.wikidata.org/entity/Q27679191

about

Targeted therapy for advanced gastric cancer: A review of current status and future prospects Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins Advances in Therapeutic Fc Engineering - Modulation of IgG-Associated Effector Functions and Serum Half-life Four individually druggable MET hotspots mediate HGF-driven tumor progression.Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.89Zr-Onartuzumab PET imaging of c-MET receptor dynamics.HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development.Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.Optimizing antibody expression by using the naturally occurring framework diversity in a live bacterial antibody display system Aptamers Binding to c-Met Inhibiting Tumor Cell Migration Generation and Characterization of an IgG4 Monomeric Fc Platform.Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program Reconstruction of 3D structures of MET antibodies from electron microscopy 2D class averages Targeted therapies in gastric cancer and future perspectives.A novel baculovirus vector for the production of nonfucosylated recombinant glycoproteins in insect cells Acquired savolitinib resistance in non-small cell lung cancer arises via multiple mechanisms that converge on MET-independent mTOR and MYC activation.Efficient production of bispecific IgG of different isotypes and species of origin in single mammalian cells.Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.Targeting the oncogenic Met receptor by antibodies and gene therapy.cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?Targeting the hepatocyte growth factor/mesenchymal epithelial transition pathway in gastric cancer: biological rationale and clinical applications.Hepatocyte growth factor and Met in drug discovery.Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.Promise and challenges on the horizon of MET-targeted cancer therapeutics Targeting c-Met in Cancer by MicroRNAs: Potential Therapeutic Applications in Hepatocellular Carcinoma.MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy.Enhancing full-length antibody production by signal peptide engineering.C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives.Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges.Development of antibody-based c-Met inhibitors for targeted cancer therapy.An affibody-adalimumab hybrid blocks combined IL-6 and TNF-triggered serum amyloid A secretion in vivo.A DNA aptamer to c-Met inhibits cancer cell migration.A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.

P2860

Q26774138-AC44FB54-8E2A-444C-BCC3-119C68D6B5EF Q26798420-7E02B7EA-BB48-42B8-ADE8-727C806AF1C2 Q28072319-01D11872-557B-466B-BFF4-581E3BDDB156 Q28079016-5C66A815-9665-4754-A641-85343DF55126 Q30581656-5DBE4EA1-D2FD-4578-B9BE-D1E4F213B71E Q33607965-F7D9EC11-EEAA-4422-8C53-4A72F1DA81B8 Q33769429-734B3EC8-965B-4BBB-885B-85E6BBB69894 Q33769437-60D406E7-66CD-4035-9DE8-B116401DAA05 Q33841490-5FCED2BA-70E0-405E-A0DB-F35293304966 Q33917507-F495DA8D-6F27-4A6F-A44F-3CE8207C37BF Q34459696-332DBD92-90F1-4DE3-9C1A-902B10948156 Q34619220-C19B21EA-D6C9-47F5-AD87-116FD659DF26 Q35692849-C484F56C-2C48-4338-B427-8EF25FA30BFC Q35859635-5CFE17E8-6C15-4DD1-AA93-F0156AB2A595 Q35866739-63E61DF4-F359-485D-9634-369D76B51C83 Q36091637-556BE053-B5D3-42E7-BEF0-AAC3FDC5D0BD Q36133180-FEFF256A-B3E7-4AC0-BE3D-E8DC21C01613 Q36345983-FF386D2D-A114-48AE-B72D-4984E125E7AE Q36471685-3C4D353F-A69A-4799-96B0-43D9A2773D84 Q37573768-3DC3E932-9DBF-46FD-8F09-58009FB5FEAC Q37628915-80C6E393-AF53-4E0D-A92A-CEAC667FABFD Q37631316-206B0772-BBA8-46A8-9A79-BD6E03BE4258 Q37739477-44165180-A578-4166-A616-A5B58DFCF88E Q38210070-E25C9B1E-C0A1-4BEE-B257-7506CB5012DC Q38214511-8740C7B4-254F-4663-AA3C-2828D75B93CE Q38216590-31049F07-DA33-45AB-B08C-8971731CBC12 Q38236096-19B61F02-13ED-45EF-98E7-AC27C79AC565 Q38263575-BB471905-86B0-4EE4-81F0-2181D2573624 Q38377273-D03F2433-0A71-4A01-A4D9-90AB388ED344 Q38383859-84A5E380-FE9E-45E2-86CF-4CC4EC7A09A2 Q38502350-24A938D6-9D07-4E43-85A2-4192065AE0A2 Q38585471-135BA228-FA52-40F0-8692-5532F89B63D3 Q38675350-5F52F4C4-98A9-4552-BF1A-66B62C14AAF5 Q38749177-457C0454-83E2-4DBC-88A0-5B213A3183EF Q38771978-7E25A9E4-00D1-4644-88EA-A329898ABC05 Q38856729-2654D070-C3F8-4888-80AC-F7729DD8F85F Q38912279-3D4F81EB-1568-40C9-9E8E-4AB4337B0AF2 Q38931171-E0E1B4D5-68B0-4735-B67B-52C15C13DF98 Q38956369-320C94FE-B8AC-42B8-A352-D54895DAA450 Q38956448-8BEBD8B9-21EB-4B4D-AC94-AAE8418FB44F

P2860

Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent

http://www.wikidata.org/entity/Q27679191

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Monovalent antibody design and ...... ctivity as a therapeutic agent

@ast

Monovalent antibody design and ...... ctivity as a therapeutic agent

@en

Monovalent antibody design and ...... ctivity as a therapeutic agent

@nl

type

label

Monovalent antibody design and ...... ctivity as a therapeutic agent

@ast

Monovalent antibody design and ...... ctivity as a therapeutic agent

@en

Monovalent antibody design and ...... ctivity as a therapeutic agent

@nl

prefLabel

Monovalent antibody design and ...... ctivity as a therapeutic agent

@ast

Monovalent antibody design and ...... ctivity as a therapeutic agent

@en

Monovalent antibody design and ...... ctivity as a therapeutic agent

@nl

P1433

Q27679191-92F50F96-1F1B-4D5E-9B93-741E88EE772A

P1476

Q27679191-B45FCAA7-3066-4A19-9183-A6204EAF76DA

P2093

Q27679191-08A7B926-6F66-4323-8152-1A9250E540D5

Q27679191-0C3E7816-14DC-4B8B-BEDF-FED571266454

Q27679191-1341B877-0171-4DDF-A042-73378E80829A

Q27679191-1BAF4607-2CE5-4A33-9364-645AA25E3A29

Q27679191-1DB64D98-5C54-4652-BFF3-D9DEFAE926EE

Q27679191-222BEF0A-E9CB-4269-BF53-C5F5D8E81212

Q27679191-2DFB2AD2-4E09-45AD-A724-BE334B03801E

Q27679191-3FBD5FD3-1366-43C8-9E5C-40A2CDF0594D

Q27679191-445CA0CE-3F59-4BAE-8C46-FF5F0E0F80A3

Q27679191-44685148-3DD1-496B-A7A0-D0353F0EC9C6

P2860

Q27679191-0036A964-4CDF-4626-BB5C-9A447D95F24D

Q27679191-0148A499-E4E3-4BCC-A902-F3057B06DDCE

Q27679191-0319B046-9448-4B04-83AB-6D2E82AEC35B

Q27679191-0D92E72A-2A5E-4A44-986F-07071F3CA1CB

Q27679191-0E5C0713-CDC4-4927-AB36-89D2A73BF19B

Q27679191-13E07048-B42D-44BD-B217-4E10C158AE7B

Q27679191-18EE06D8-A000-4DB8-9AC6-B9EC38E92E28

Q27679191-1B988363-CBE4-4E4C-A358-7AC92BE97946

Q27679191-1DE134E3-69B3-49E3-A185-537AB2FEC5FA

Q27679191-22697672-1FBE-4F2D-87FC-AC380115DA29

P304

Q27679191-DD8E7CB1-7FAC-46C2-9F37-EF43FD09EF21

P31

Q27679191-0FCA1218-9755-4AC5-8E31-E73FFEFDEC2F

P3181

Q27679191-4C506FF1-E3AB-4728-AB7D-17E54858BE66

P356

Q27679191-7576FE84-E0E9-489A-8BEC-725F2E96BCED

P407

Q27679191-B478C54C-76F1-4275-A5D1-566FC44A30FE

P433

Q27679191-CE751693-F817-41AC-A21B-BF5188FBA990

P478

Q27679191-054105C3-0102-417B-91A6-A368B599FE58

P50

Q27679191-34EF45ED-34DE-4705-96FB-14EB9AC4C534

P577

Q27679191-60B4FE90-3881-4738-A29F-687EBB20E6EE

P5875

Q27679191-3D586D5D-55A0-4A6D-861F-9B4EF9283125

P698

Q27679191-8C7443A4-E268-49AA-A58D-F59BF053A3FC

P921

Q27679191-3DE6AC46-38CB-47E1-B480-83046C8A150A

P932

Q27679191-023FFAAA-AAE8-4F1B-B821-4C04978285C9

P3181

P356

PNAS.1302725110

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Monovalent antibody design and ...... ctivity as a therapeutic agent

@en

P2093

Amy Lim

http://www.w3.org/2001/XMLSchema#string

Arthur Huang

http://www.w3.org/2001/XMLSchema#string

Barbara Moffat

http://www.w3.org/2001/XMLSchema#string

Dafna W Kaufman

http://www.w3.org/2001/XMLSchema#string

Daniel G Yansura

http://www.w3.org/2001/XMLSchema#string

Dorothea E Reilly

http://www.w3.org/2001/XMLSchema#string

Eileen T Duenas

http://www.w3.org/2001/XMLSchema#string

Elaine Mai

http://www.w3.org/2001/XMLSchema#string

George F Vande Woude

http://www.w3.org/2001/XMLSchema#string

Heidi S Phillips

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the HGF beta-chain in complex with the Sema domain of the Met receptor

Structure of the human receptor tyrosine kinase met in complex with the Listeria invasion protein InlB

Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity

Humanization of an anti-p185HER2 antibody for human cancer therapy

Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells

PHENIX: a comprehensive Python-based system for macromolecular structure solution

Processing of X-ray diffraction data collected in oscillation mode

Crystal structure of the NK1 fragment of human hepatocyte growth factor at 2.0 A resolution

Inference of macromolecular assemblies from crystalline state

How to measure and predict the molar absorption coefficient of a protein

P304

E2987-96

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2779677

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.1302725110

http://www.w3.org/2001/XMLSchema#string

P407

P433

32

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-07-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

251570223

http://www.w3.org/2001/XMLSchema#string

P698

23882082

http://www.w3.org/2001/XMLSchema#string

P921

P932

3740879

http://www.w3.org/2001/XMLSchema#string